Press Release: New L version of the I.DOT: Now Available

August 31, 2022 –DISPENDIX, a BICO company, has announced the launch of the I.DOT L, a new version of the I.DOT non-contact dispenser designed to better address genomics applications such as NGS Library Preparation and qPCR.

The I.DOT non-contact dispenser has provided researchers with the ability to precisely and efficiently dispense up to 96 different samples or reagents at a volume range from eight nanoliters to tens of microliters since the release of the product in 2016.

Since the I.DOT is so simple to use and the proprietary source consumable only wastes one microliter of dead volume for each source liquid dispensed, genomics researchers across the globe have adopted the technology for dispensing prcious enzymes such as PCR mastermixes and fragmentation, ligation, and amplification reagents for NGS libarary preparation workflows.

With the I.DOT L, DISPENDIX has responded to direct feedback from customers reporting that increased source-well volumes would allow for a more efficient automation of the genetic analysis workflow.  The I.DOT L.100 source wells have an increased source volume capacity of 500 uL compared to the historical 80 uL source volume capacity, allowing researchers to use less wells, saving plastics and reagent consumption when dispensing their enzymes.

“As pioneers in the liquid handling space, we continue to innovate and shape the future of health,” said Petros Apostolopoulos, CEO of DISPENDIX. “We are excited to announcethat we have developed a new product to improve workflows in life science research labs, bringing a higher level of automation, precision, and speed to the entire industry."

The I.DOT carries out precise and accurate noncontact liquid handling tasks via eight individually controlled positive pressure channels that generate droplets from 8 to 50 nanoliters from a small nozzle at the bottom of each well. Each channel can generate up to 100 droplets per second giving control and speed to the users all while eliminating cross contamination.  Further, the I.DOT provides a high-degree of process safety to researchers through a droplet detection feature that verifies the actual dispense volume for each liquid handling task.

This launch is the latest in DISPENDIX’s mission to deliver simple and elegant solutions for nanoliter dispensing. The I.DOT L is now available; those interested can visit To learn more about the I.DOT L visit or contact sales@dispendix.com

About DISPENDIX

DISPENDIX GmbH, the premier provider of noncontact liquid handling solutions in the nano to microliter range, started out in 2016 as a spin-off from the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) in Stuttgart, Germany. In 2018, DISPENDIX joined the world’s leading bio convergence company BICO, which now encompasses 900+ colleagues and 11 companies, offering a portfolio of technologies, products and services to create the future of health. Part of that portfolio is DISPENDIX’s patented and widely recognized technology, the I.DOT, which brings intuitive automation, precision, and speed to every lab, allowing scientists to optimize liquid handling workflows and accelerate their research in a range of applications. DISPENDIX’S Liquid handling technology enables new discoveries in areas such as drug development, diagnostics and synthetic biology. We believe that technological advances and science are made for each other. Good technology simplifies science. www.dispendix.com

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.  The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm